J&J partners with San Diego startup Cue to develop portable HIV viral load Dx

At-home diagnostic test for testosterone, fertility, inflammation, vitamin D and influenza--Courtesy of Cue

Johnson & Johnson ($JNJ) has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.

Cue is backed by Sherpa Ventures, which was co-founded by early Uber backer Shervin Pishevar. The firm led a $7.5 million investment in the at-home diagnostics developer in late 2014. Its core project is an at-home diagnostic test for testosterone, fertility, inflammation, vitamin D and influenza. The company has previously said it was aiming for a late 2015 approval of that device, dubbed Cue. But on any word of FDA approval, the company has been mum thus far.

Using Cue, users insert a small bodily fluid sample with results sent from it via Bluetooth to an iPhone app. It's slated to cost $199 with single-use cartridges for $4 each.

The J&J deal indicates that Cue has broadened its ambitions from those for early adopters in the U.S to vital tests needed in poor nations. The expectation is that a J&J-Cue HIV viral load test would improve disease management for people living with HIV all over the world, particularly in the places with sizable HIV-infected populations such as Africa, India and Southeast Asia.

Cue CEO Ayub Khattak

"We're excited to work with Janssen, a leader in the HIV field, to accelerate the development of the HIV quantitative viral load test on Cue's platform," said Cue CEO Ayub Khattak in a statement. "Together we can make a big impact on this significant global health challenge by bringing simplicity, immediacy and affordability to the field of HIV viral load testing in an unprecedented way."

- here is the announcement


Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.